THDB(SH:600867) Shang Hai Zheng Quan Bao·2025-11-03 18:20Core Points - The company held its third extraordinary general meeting of shareholders on November 3, 2025, with no resolutions being rejected [2][5] - The meeting was convened by the board of directors and chaired by Chairman Li Jiahong, utilizing a combination of on-site and online voting methods [2][5] Group 1: Meeting Details - The meeting was attended by all nine current directors and three supervisors, with the presence of senior management [3][4] - Several governance-related proposals were passed, including the cancellation of the supervisory board and amendments to the company's articles of association [3][4] - The voting results were deemed legal and valid, in compliance with relevant laws and regulations [5] Group 2: Board Changes - Director Zhang Guodong submitted a resignation letter due to internal work adjustments but will continue as the company's deputy general manager [8][9] - Zhang Guodong was elected as a representative director of the employee board during the ninth fourth employee representative conference held on November 3, 2025 [8][10] - His resignation does not affect the minimum number of board members required by law and will not disrupt the normal operations of the board [9][10] Group 3: Director Profile - Zhang Guodong, born in August 1976, holds a bachelor's degree in clinical medicine and an MBA [12] - He has a history of working in the pharmaceutical industry, including roles at Federal Pharmaceuticals and Eli Lilly, before joining the company in 2005 [12] - As of the announcement date, he holds 264,120 shares of the company, representing 0.01% of the total share capital [12]